Puma Biotechnology (PBYI) Stock Price, Quote & News

Company Profile

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A fo...

Industry: Biotechnology

Sector: Healthcare

Phone: 424 248 6500

Website: www.pumabiotechnology.com

Address:

10880 Wilshire Boulevard, Suite 1700, Los Angeles, United States

OfficialStocktwitsUser Mar. 16 at 7:54 PM

$PBYI RSI: 33.64, MACD: -0.1848 Vol: 0.59, MA20: 6.50, MA50: 6.50 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

RadioIsotope25 Mar. 14 at 2:54 PM

Big opportunity in HER2 at $RADX (Radiopharm Theranostics) $CELC $SMMT $PBYI

0 · Reply

ZacksResearch Mar. 12 at 4:41 PM

$IRWD vs. $PBYI — Which small-cap biotech actually has the edge right now? Both companies are building around a single commercial drug, and sales from those therapies are expected to support their 2026 revenues—GI treatments for Ironwood and cancer therapy from Puma Biotechnology. That puts a lot of weight on how those products perform. ⚖️ See which stock looks like the better buy 👉 https://www.zacks.com/stock/news/2883283/irwd-vs-pbyi-which-small-cap-biotech-stock-is-a-better-buy?cid=sm-stocktwits-2-2883283-teaser-37187&ADID=SYND_STOCKTWITS_TWEET_2_2883283_TEASER_37187

0 · Reply

ZacksResearch Mar. 12 at 3:41 PM

$IRWD vs. $PBYI: Which Biotech Stock is the Better Bet? 🤔 Ironwood's Linzess sales outlook shows a promising 54% revenue boost in 2026, while Puma's Nerlynx faces a cautious growth path despite rising demand. Plus, IRWD's EPS is expected to increase by 533% in 2026! 🚀 Discover why Ironwood might be the smarter pick here 👉 https://www.zacks.com/stock/news/2883283/irwd-vs-pbyi-which-small-cap-biotech-stock-is-a-better-buy?cid=sm-stocktwits-2-2883283-body-37188&ADID=SYND_STOCKTWITS_TWEET_2_2883283_BODY_37188

0 · Reply

Jonnyking Mar. 11 at 5:20 PM

$PBYI Alan, for once, please share the positive data with us, you promised on Q4 2025, then Q1 2026 and now Q2 2026.... Only the positive data can save you and us

2 · Reply

free2dream Mar. 5 at 5:21 PM

$PBYI how is this valued at only 313M market cap ?Seems undervalued

0 · Reply

BillionerOfKing Mar. 3 at 4:40 PM

$PBYI Current Stock Price: $6.17 Contracts to trade: $5.0 PBYI Mar 20 2026 Call Entry: $1.05 Exit: $1.86 ROI: 77% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

StockScanners Mar. 3 at 6:37 AM

$PBYI keep watch if this holds above 6.05

0 · Reply

PSDL75 Mar. 2 at 8:08 PM

$PBYI trading around Jonny is profitable

1 · Reply

tsingyuanTemp Mar. 2 at 8:07 PM

$PBYI you guys listen to the confernece? Nothing big for the two phase 2 trials. Did I miss anything?

1 · Reply

Puma Biotechnology, Inc. (PBYI) Q4 2025 Earnings Call Transcript

Feb 26, 2026, 4:05 PM EST - 23 days ago

Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 23, 2026, 4:15 PM EST - 26 days ago

Puma Biotechnology to Present at TD Cowen's 46th Annual Health Care Conference

Feb 12, 2026, 4:07 PM EST - 5 weeks ago

Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2025 Financial Results

Feb 4, 2026, 5:05 PM EST - 6 weeks ago

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Dec 22, 2025, 4:10 PM EST - 3 months ago

Puma Biotechnology Added to the NASDAQ Biotechnology Index (NBI)

Nov 10, 2025, 6:02 AM EST - 4 months ago

Puma Biotechnology: Step By Step In Making A Transition

Nov 7, 2025, 1:16 PM EST - 4 months ago

Puma Biotechnology, Inc. (PBYI) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:05 PM EST - 4 months ago

Puma Biotechnology Reports Third Quarter 2025 Financial Results

Oct 23, 2025, 4:10 PM EDT - 5 months ago

Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results

Sep 2, 2025, 4:07 PM EDT - 7 months ago

Puma Biotechnology to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 7, 2025, 8:53 PM EDT - 8 months ago

Puma Biotechnology, Inc. (PBYI) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 8 months ago

Puma Biotechnology Reports Second Quarter Financial Results

Jul 24, 2025, 4:15 PM EDT - 8 months ago

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2025 Financial Results

Jun 25, 2025, 11:06 AM EDT - 9 months ago

Puma Biotechnology: Updated Timelines And A Resurgence In Sentiment

May 9, 2025, 9:08 AM EDT - 11 months ago

Puma Biotechnology, Inc. (PBYI) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:05 PM EDT - 11 months ago

Puma Biotechnology Reports First Quarter Financial Results

Apr 30, 2025, 6:00 AM EDT - 11 months ago

Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX® (neratinib) for Breast Cancer Patients

Apr 28, 2025, 3:03 PM EDT - 11 months ago

Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025

Apr 24, 2025, 4:11 PM EDT - 11 months ago

Puma Biotechnology to Host Conference Call to Discuss First Quarter 2025 Financial Results

Mar 31, 2025, 4:53 AM EDT - 1 year ago

Puma SE: Undervalued With Tailwinds Ahead

Mar 26, 2025, 9:00 AM EDT - 1 year ago

Puma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025

Mar 21, 2025, 7:46 AM EDT - 1 year ago

PUMA SE: This Is The Right Time To Buy

Mar 5, 2025, 5:30 PM EST - 1 year ago

Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference

Feb 27, 2025, 9:02 PM EST - 1 year ago

Puma Biotechnology, Inc. (PBYI) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:05 PM EST - 1 year ago

Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 26, 2025, 4:15 PM EST - 1 year ago

Puma Biotechnology to Present at TD Cowen's 45th Annual Health Care Conference

Feb 13, 2025, 4:15 PM EST - 1 year ago

Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results

Dec 23, 2024, 9:01 AM EST - 1 year ago

Puma Biotechnology's NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation

Dec 16, 2024, 11:36 AM EST - 1 year ago

Puma Biotechnology: Continuing To Push Their Aurora Kinase Story Forward

Nov 20, 2024, 8:57 AM EST - 1 year ago

Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Nov 7, 2024, 11:09 PM EST - 1 year ago

Puma Biotechnology, Inc. (PBYI) Q3 2024 Earnings Conference Call Transcript

Nov 7, 2024, 4:05 PM EST - 1 year ago

Puma Biotechnology Reports Third Quarter 2024 Financial Results

Sep 3, 2024, 4:15 PM EDT - 1 year ago

Puma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 1, 2024, 10:54 PM EDT - 1 year ago

Puma Biotechnology, Inc. (PBYI) Q2 2024 Earnings Call Transcript

Jul 18, 2024, 4:10 PM EDT - 1 year ago

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2024 Financial Results

Jun 3, 2024, 2:33 PM EDT - 1 year ago

Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer

Jun 2, 2024, 10:01 AM EDT - 1 year ago

Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)

May 28, 2024, 9:00 AM EDT - 1 year ago

Puma Biotechnology to Join Russell 3000 Index

May 23, 2024, 5:15 PM EDT - 1 year ago

Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting

May 2, 2024, 10:11 PM EDT - 2 years ago

Puma Biotechnology, Inc. (PBYI) Q1 2024 Earnings Call Transcript

Apr 18, 2024, 4:15 PM EDT - 2 years ago

Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results

Mar 20, 2024, 8:30 AM EDT - 2 years ago

Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

Feb 29, 2024, 8:39 PM EST - 2 years ago

Puma Biotechnology, Inc. (PBYI) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 4:05 PM EST - 2 years ago

Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 22, 2024, 4:10 PM EST - 2 years ago

Puma Biotechnology to Participate in a Panel Discussion at TD Cowen's 44th Annual Health Care Conference

Feb 15, 2024, 4:10 PM EST - 2 years ago

Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results

Feb 13, 2024, 8:30 AM EST - 2 years ago

Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer

Jan 11, 2024, 4:07 PM EST - 2 years ago

Puma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference

OfficialStocktwitsUser Mar. 16 at 7:54 PM

0 · Reply

RadioIsotope25 Mar. 14 at 2:54 PM

Big opportunity in HER2 at $RADX (Radiopharm Theranostics) $CELC $SMMT $PBYI

0 · Reply

ZacksResearch Mar. 12 at 4:41 PM

0 · Reply

ZacksResearch Mar. 12 at 3:41 PM

0 · Reply

Jonnyking Mar. 11 at 5:20 PM

$PBYI Alan, for once, please share the positive data with us, you promised on Q4 2025, then Q1 2026 and now Q2 2026.... Only the positive data can save you and us

2 · Reply

free2dream Mar. 5 at 5:21 PM

$PBYI how is this valued at only 313M market cap ?Seems undervalued

0 · Reply

BillionerOfKing Mar. 3 at 4:40 PM

0 · Reply

StockScanners Mar. 3 at 6:37 AM

$PBYI keep watch if this holds above 6.05

0 · Reply

PSDL75 Mar. 2 at 8:08 PM

$PBYI trading around Jonny is profitable

1 · Reply

tsingyuanTemp Mar. 2 at 8:07 PM

$PBYI you guys listen to the confernece? Nothing big for the two phase 2 trials. Did I miss anything?

1 · Reply

MahiMe Mar. 2 at 3:05 PM

$PBYI conference today..

0 · Reply

PSDL75 Mar. 2 at 12:09 PM

$PBYI Jonny bearish with a low price target...Cinderella bearish... can't be a bigger buy sign....red to green here on a bad day or week.. Today will be interesting

0 · Reply

Jonnyking Feb. 28 at 1:19 AM

$PBYI dang, no data release? the only way that we can be saved is the release of promising data and Alan hit selling button, otherwise, we are heading to 4-5.... lost all the gains from last 3 months in one day, no fun

2 · Reply

Jruiner Feb. 27 at 10:17 PM

$PBYI par for the course if you’ve been here long enough

1 · Reply

ZacksResearch Feb. 27 at 6:53 PM

$PBYI beats big… and still gets crushed 14% after hours. What gives? ⚠️ Q4 earnings topped estimates and revenue jumped 28%, a strong print by any standard. But the weak 2026 outlook spooked the market, overshadowing the beat and triggering a sharp selloff. Is this an overreaction or a warning shot? Full breakdown here 👉 https://www.zacks.com/stock/news/2876997/pbyi-q4-earnings-sales-beat-estimates-stock-down-on-weak-2026-view?cid=sm-stocktwits-2-2876997-teaser-35605&ADID=SYND_STOCKTWITS_TWEET_2_2876997_TEASER_35605

0 · Reply

Bazzil Feb. 27 at 6:32 PM

$PBYI is this drop also related to Zongertinib approval? Next gen her 2 TK inhibitor with better side effect profile.

1 · Reply

ZacksResearch Feb. 27 at 5:53 PM

$PBYI Q4 earnings beat, but shares tumble 14% on weak 2026 guidance. 📉 🔹 EPS of 29 cents tops estimates 🔹 Q4 revenue up 28% YoY thanks to Nerlynx and royalty growth 🔹 Disappointing 2026 outlook: Total revenue guidance below Zacks Consensus Estimate Full analysis here 👉 https://www.zacks.com/stock/news/2876997/pbyi-q4-earnings-sales-beat-estimates-stock-down-on-weak-2026-view?cid=sm-stocktwits-2-2876997-body-35604&ADID=SYND_STOCKTWITS_TWEET_2_2876997_BODY_35604

0 · Reply

PSDL75 Feb. 27 at 4:05 PM

$PBYI you sell Jonny and buy Cinderella...

0 · Reply

Cinderella7474 Feb. 27 at 3:54 PM

$PBYI the way is clear to 4,9-4,75

0 · Reply

PSDL75 Feb. 27 at 3:34 PM

$PBYI Jonny took yall to the woodshed

1 · Reply

Cinderella7474 Feb. 27 at 3:25 PM

$PBYI haha. Jhonny is the best anti person. If he says long, then it's definitely short.

0 · Reply

Itinerant Feb. 27 at 1:46 PM

$PBYI The guidance is a low ball figure. It is even lower than the Q4 revenue annualized.

2 · Reply

Market Cap	311.36M
Revenue (ttm)	228.37M
Net Income (ttm)	31.11M
EPS (ttm)	N/A
PE Ratio	10.08
Forward PE	26.17
Profit Margin	13.62%
Debt to Equity Ratio	0.17

Volume	340,200
Avg Vol	435,828
Day's Range	N/A - N/A
Shares Out	50.88M
Stochastic %K	55%
Beta	1.26
Analysts	Hold
Price Target	$3.50